AU2004220053A1 - Weak base salts - Google Patents

Weak base salts Download PDF

Info

Publication number
AU2004220053A1
AU2004220053A1 AU2004220053A AU2004220053A AU2004220053A1 AU 2004220053 A1 AU2004220053 A1 AU 2004220053A1 AU 2004220053 A AU2004220053 A AU 2004220053A AU 2004220053 A AU2004220053 A AU 2004220053A AU 2004220053 A1 AU2004220053 A1 AU 2004220053A1
Authority
AU
Australia
Prior art keywords
salt
pharmaceutical composition
carbendazim
hydrogen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004220053A
Other languages
English (en)
Inventor
Tapan Sanghvi
Samuel H. Yalkowsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/402,347 external-priority patent/US7022712B2/en
Application filed by University of Arizona filed Critical University of Arizona
Publication of AU2004220053A1 publication Critical patent/AU2004220053A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004220053A 2003-03-12 2004-03-12 Weak base salts Abandoned AU2004220053A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45403503P 2003-03-12 2003-03-12
US60/454,035 2003-03-12
US45451403P 2003-03-13 2003-03-13
US60/454,514 2003-03-13
US10/402,347 US7022712B2 (en) 2002-03-26 2003-03-26 Solubilization of weak bases
US10/402,347 2003-03-26
PCT/US2004/007786 WO2004081006A1 (en) 2003-03-12 2004-03-12 Weak base salts

Publications (1)

Publication Number Publication Date
AU2004220053A1 true AU2004220053A1 (en) 2004-09-23

Family

ID=32995897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004220053A Abandoned AU2004220053A1 (en) 2003-03-12 2004-03-12 Weak base salts

Country Status (6)

Country Link
EP (1) EP1606290A1 (https=)
JP (1) JP2006519852A (https=)
AU (1) AU2004220053A1 (https=)
CA (1) CA2515289A1 (https=)
MX (1) MXPA05009564A (https=)
WO (1) WO2004081006A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2742790C (en) * 2008-11-19 2018-02-13 Cephalon, Inc. Novel forms of an indazolo[5,4-a]pyrrolo [3,4-c] carbazole compound
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195180A (en) * 1967-05-05 1970-06-17 Du Pont Use of Alkyl 2-Benzimidazole-Carbamate Salts a Fungicides
CA962588A (en) * 1972-05-17 1975-02-11 Her Majesty In Right Of Canada As Represented By The Minister Of The Env Ironment, And Canadian Patents And Development Limited Method, apparatus, and fungicides for the treatment of trees subject to dutch elm disease and other fungus diseases
JPS5459338A (en) * 1977-10-20 1979-05-12 Takeda Chem Ind Ltd Remedy for dermatomycosis
HU199431B (en) * 1985-02-04 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing carbendazim salts, and fungicide comprising such carbendazim salt as active ingredient
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer

Also Published As

Publication number Publication date
CA2515289A1 (en) 2004-09-23
EP1606290A1 (en) 2005-12-21
WO2004081006A1 (en) 2004-09-23
MXPA05009564A (es) 2005-11-17
JP2006519852A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
AU2004220053A1 (en) Weak base salts
ES2946489T3 (es) Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida
AU2011213431B2 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
US10519176B2 (en) Crystalline forms
Caira et al. Polymorphism and pseudopolymorphism of the antibacterial nitrofurantoin
EP1494998A2 (en) Multiple-component solid phases containing at least one active pharmaceutical ingredient
JP2009542785A (ja) 短時間作用型ベンゾジアゼピンの塩およびそれらの多形形態
BR112016002770B1 (pt) Sal de hemissulfato de ácido 5,10-metileno-(6r)-tetra-hidrofólico, sua composição farmacêutica e seu uso
ES2887020T3 (es) Novedosa preparación que contiene derivado de bencimidazol
US20070043070A1 (en) Weak base salts
Mannava et al. Solubility and permeability enhancement of BCS class IV drug ribociclib through cocrystallization
ES3055682T3 (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
An et al. Exploring the differences in crystal structure landscapes and physicochemical properties of enrofloxacin through the number of-OH in coformers: A case study
US8530501B2 (en) Salts and crystalline forms of a factor Xa inhibitor
Firmino et al. The free hydralazine anti-hypertensive drug and new salts with improved solubility
CN109232582B (zh) 拉洛替尼硫酸氢盐晶型及其制备和应用
JP7665219B2 (ja) 化合物の塩、及び塩を含む医薬組成物
BRPI0719568A2 (pt) Derivados de amino quinazolinas com propriedades de redução de plaquetas sanguíneas
WO2000058310A1 (en) Zolpidem salts
CN103841828A (zh) 德尼布林二盐酸盐
Voronin et al. Trimorphism in riluzole salicylate: screening, crystal structures and solution thermodynamics
KR102281890B1 (ko) 실로스타졸의 제조방법 및 이를 포함하는 약학제제
BR102021009918A2 (pt) Dispersão sólida do antibiótico rifampicina
Sanghvi Formulation development of anticancer drug: FB642
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application